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ABSTRACT
Chemokines are essential mediators of cellular trafﬁcking, interactions and tumor development. Though
adoptive cell therapy (ACT) has been a tremendous success in the treatment of metastatic melanoma
(MM), a major obstacle for successful ACT, is limited homing of effector T cells to immune suppressive
tumor sites. We hypothesized that equipping T cells with chemokine receptors matching the chemokines
of the tumor microenvironment, could improve tumor homing of T cells. T cells from malignant ascites (n
D 13); blood from ovarian cancer (OC) patients (n D 14); and healthy donors (n D 13) were analyzed by
ﬂow cytometry. We found that FoxP3C regulatory T cells accumulation in patients with OC associates with
CCR4 expression. We characterized a chemokine proﬁle of ascites chemokines, and expression of
corresponding receptors on circulating T cells and tumor ascites lymphocytes (TALs). CCL22, CXCL9,
CXCL10 and CXCL12 associated with enrichment of CCR4C, CCR5C, CXCR3C and CXCR4C T cells in ascites.
Circulating T cells and TALs however did not express CXCR2, identifying CXCR2 as candidate for
chemokine receptor transduction. TALs readily expressed IFNg and TNFa upon stimulation despite the
frequency decreasing with in vitro expansion. Lentiviral transduction of TALs (n D 4) with chemokine
receptor CXCR2 signiﬁcantly increased transwell migration of TALs towards rhIL8 and autologous ascites.
The majority of expanded and transduced TALs were of a T effector memory subtype. This proof of
concept study shows that chemokine receptor engineering with CXCR2 is feasible and improves homing
of transduced TALs towards the OC microenvironment.
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Introduction
Tumor inﬁltrating lymphocytes (TILs) have repeatedly been
shown to correlate with better prognostic outcome in malig-
nant melanoma (MM),1,2 colorectal cancer3 and ovarian cancer
(OC) of serous histology.4,5 Adoptive cell therapy (ACT) trans-
ferring in vitro expanded TILs back to patients has been very
successful in the treatment of malignant melanoma,6-8 and
while ACT of MM has entered phase III clinical testing, focus
has shifted to identifying other clinical malignancies that might
beneﬁt from ACT.
With an estimated 239.000 new cases and 152.000 deaths
every year, OC represents the 8th most common cause of can-
cer deaths worldwide (World cancer report 2014, WHO).9 Due
to the anatomical location in the peritoneal cavity, diagnosis is
most often made when the disease has spread, and/or is giving
rise to formation of ascites. Partly due to late diagnosis and
development of chemotherapy resistance, OC mortality is the
highest among gynecological cancers.9,10
Chemokine receptors are classically associated with orches-
trating immune responses by directing the immune cells to the
appropriate anatomic site. Expression of CCR7 by na€ıve T cells
is responsible for recruitment and entry of T cells to the lymph
nodes (LNs) via high endothelial venules (HEVs), whereas
CCR7 is downregulated and CCR5 and CXCR3 upregulated
upon antigen-speciﬁc activation by dendritic cells in the LNs,
to allow exit and homing to site of inﬂammation.11
Chemokines in the tumormicroenvironment neatly orchestrate
cellular migration and cell-cell interaction, with great impact on
tumor development.12 Cells of the tumor microenvironment
(cancer cells, stromal cells, immune cells) release a wide range of
chemokines mediating recruitment of different cell subsets of pro-
and antitumor responses. Among others, recruitment of regulatory
T cells (Tregs) to the tumor site has long been implicated in foster-
ing suppression of anti-cancer immune responses in different
cancers.13 In addition to their classical role inducing cellular migra-
tion, chemokines are involved in other processes of tumor
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progression, inducing tumor cell proliferation, angiogenesis, resis-
tance to chemotherapy, andmetastasis.14
ACT in its current classical form, is rather simple, and deliv-
ery of T cells to the tumor site after intravenous (i.v) transfer, is
a limiting factor for success of treatment. While early ACT
studies in ovarian cancers have explored both i.v.15 and intra
peritoneal16 transfer of TILs, clear data showing beneﬁt of TIL
ACT is still lacking. We hypothesize that it is possible to exploit
the existing pro-tumorigenic chemokine axes in OC and – by
genetic engineering with tumor speciﬁc chemokine receptor(s)
– can thus improve homing of T cells to the tumor site.
We characterized the chemokine proﬁle of 10 select chemo-
kines in ascites from patients diagnosed with OC and their corre-
sponding receptors on tumor ascites lymphocytes (TALs), to
investigate whether T cell homing to OC can be improved by
equipping TALs with chemokine receptors matching the chemo-
kines of the tumor.
Results
Regulatory T cells accumulate in ascites of ovarian cancer
patients
We analyzed Treg frequencies in blood (n D 14) and ascites
(n D 13) from patients with OC by multicolor ﬂow cytome-
try. Tregs were gated as the CD127low CD25hi FoxP3C frac-
tion of CD3C CD4C cells (Fig. 1A-B). Treg frequencies are
signiﬁcantly higher in ascites of patients with OC, compared
to healthy donor (HD) reference PBMC (p D 0.0005). In
addition, PBMC Treg levels seems to be slightly increased
among patients with OC compared HD reference PBMC
Treg levels (p D 0.07) (Fig. 1C). CD4/CD8 ratios were iden-
tical across OC ascites, OC PBMC and healthy donor sam-
ples (suppl. Fig. 1). Additionally, we found that MFI of
FoxP3 was higher on Tregs from OC ascites compared to
Tregs in the blood of both OC patients and healthy donors
Figure 1. Regulatory T cells accumulate in ovarian cancer ascites. Frequencies of regulatory T cells were analysed by ﬂow cytometry of peripheral blood mononuclear cells
(PBMC) and ascites from patients with ovarian cancer (OC) compared to PBMC from healthy donors (HD). Tregs were gated as CD25hi CD127low/neg cells out of total live
CD3C CD4C T cells. A) Representative dot plots of CD25hi CD127low/neg gating from HD PBMC, OC PBMC and OC Ascites respectively. B) Representative histograms of
FoxP3 and CCR4 MFI of Tregs from OC ascites show a higher expression of FoxP3 and CCR4 compared to Tregs from HD PBMC and OC PBMC. C) Percentages of FoxP3C
Tregs and D) percentage of CCR4C FoxP3C Tregs in HD, OC PBMC and OC ascites. HD PBMC nD 13, OC PBMC nD 14, OC Ascites nD 13, Unpaired t-test, error bars desig-
nate mean with SEM, P < 0.05, P < 0.01,  P < 0.001.
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(P<0.001, Fig. 1B and suppl. Fig. 1), representing a func-
tionally more suppressive phenotype of Tregs17,18 in the
tumor ascites. To assess whether this directional accumula-
tion of Tregs from blood to OC ascites was associated with
expression of chemokine receptor CCR4, FoxP3C Tregs
were further sub-gated on CCR4 expression (Fig. 1B-C).
Data show a trend towards increased levels of CCR4C on
Tregs (80.2%) in ascites compared to blood of OC patients
(72.9%, p D 0.08) and signiﬁcantly enriched levels com-
pared to Tregs in blood of healthy donors (60.0%,
p D 0.0003). This suggests that Treg home to OC ascites in
a CCR4 associated manner.
Chemokine proﬁling of OC ascites reveals several potential
immune cell recruitment axes
Chemokine concentrations of 10 selected chemokines (CCL2,
CCL5, CCL17, CCL22, CXCL1, CXCL8, CXCL9, CXCL10,
CXCL11, CXCL12) in cell free ascites were analyzed by Lumi-
nex. As chemokine mediated leukocyte recruitment is concen-
tration-gradient dependent, we set a hypothetical threshold of
100 pg/ml, to only assess chemokines present in concentrations
relevant for recruitment of immune cells.
As expected, CCR4 ligand CCL22 was found across all
tested OC ascites samples tested (Fig. 2A, n D 13, median
285.3 pg/ml, range 151.2–574.6 pg/ml), consistent with an
enrichment of CCR4C Tregs in ascites of patients with OC
compared to the blood (Fig. 1).
CXCR2 ligands, CXCL1 (Gro-a) and CXCL8 (IL-8, median
254.5 and 254.1 pg/ml respectively); CXCR3 ligands, CXCL9
(median 338.7 pg/ml) and CXCL10 (median 4209 pg/ml); and
CXCR4 ligand CXCL12 (SDF-1, median 908 pg/ml), were
found at varying but high levels (Fig. 2A).
CCL2 CCL5, CCL17 and CXCL11 were found to be below
the threshold of 100 pg/ml in the majority of samples, and thus
were not examined further.
Characterization of chemokine receptor expression on T
cells from ovarian cancer patients
We characterized the chemokine receptor expression on T cells
from OC ascites and OC PBMC by multicolor ﬂowcytometry
(gating strategies, suppl. Fig. 2). Chemokine receptors classi-
cally associated with activation of T cells after priming in the
lymph nodes, CCR5 and CXCR3, were expressed on a larger
fraction of T cells from OC ascites compared to T cells found
in the blood of patients with OC (e.g. 58.4% vs. 41.2%, p D 0.02
and 43.3% vs. 13.4% p D 0.003 respectively for CD8C T cells)
(Fig. 2B). Despite expression of CXCR4 on the majority of both
OC ascites (87.45%) and OC PBMC T cells (72.3%), the fre-
quency of CXCR4C was signiﬁcantly higher among ascites T
cells (CD8C T cells p D 0.01, CD4C T cells p D 0.0001).
CXCR2, a receptor most commonly found on neutrophils, was
Figure 2. Chemokines and chemokine receptors in ovarian cancer. (A) 10-plex Luminex analyses of chemokine concentration (pg/ml) in cell free ascites (n D 13). 3 sam-
ples (one from CXCL8, and 2 from CXCL10) were excluded in the graph as they were out of range ( > 5000 pg/ml). (B) Expression of corresponding chemokine receptors
on CD4C and CD8C T cells from ascites (blue bars, n D 13) and PBMC (gray bars, n D 14) of patients with serous adenocarcinoma of the ovaries. Unpaired t-test, error
bars designate mean with SEM, P < 0.05, P < 0.01,  P < 0.001.
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not expressed on T cells from neither OC PBMC nor OC asci-
tes (see suppl. Fig. 3D).
Though the expression patterns in general were very similar
between CD4C and CD8C T cells from ascites of patients with
OC, a larger fraction of CD8C T cells stained positive for che-
mokine receptor compared to CD4C T cells. The only exception
to this was that approx. 40% of CD4C T cells expressed the che-
mokine receptor CCR4 (46% of OC Ascites T cells and 36% of
Figure 3. Maturation proﬁle of peripheral blood T cells and TALs from ovarian cancer patients. The maturation proﬁle of peripheral blood T cells, ex vivo TALs, young TALs
and transduced REP TALs was assessed by the distribution of na€ıve, Tcm, Tem and Temra cells gated out of the live CD3C T cell population. (A) Representative dot plots of
gating strategy: CD45RA expression gated on the CD3C T cells, and further subgated by CD62L and CD57 expression. (B-E) Frequencies of Tna€ıve, Temra, Tem and Tcm,
respectively, in OC PBMC (n D 12), ex vivo ascites (n D 12), young TAL cultures (n D 10) and REP TAL cultures (n D 8, 4 MOCK and 4 CXCR2 transduced). (F) Pie charts of
maturation proﬁle (mean) of Tna€ıve, Temra, Tem and Tcm represented in B-E in addition to CD57C Tem and “other”, as shown in gating strategy (A). Error bars designate
standard deviation (SD), P < 0.05, P < 0.01 and P < 0.001.
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OC PBMC) compared to only 14% of CD8C T cells, consistent
with our ﬁndings of an enriched CCR4 expressing Treg popula-
tion in ascites and blood from OC patients.
Apart from CCR5, the differentially expressed chemokine
receptors CCR4 (on CD4C T cells), CXCR3 and CXCR4 on
ascites T cells were in line with our ﬁndings that the matching
ligands were among the chemokines found at highest concen-
trations in clariﬁed ascites (see Fig. 2).
While we ﬁnd an enrichment of chemokine receptor positive T
cells in ascites compared to OC PBMC, no differential chemokine
receptor expression was found between PBMC of patients with OC
and healthy donors (suppl. Fig. 3). Furthermore, chemokines
CCL2, CCL22, CXCL8, CXCL9 and CXCL10 were found at higher
levels in OC ascites (ascites cohort) compared to plasma from OC
patients (PBMC cohort) (suppl. Fig. 4, for patient characteristics
see suppl. table 1), supporting the notion of a chemokine gradient.
Figure 4. Cytokine proﬁle of stimulated peripheral blood T cells and TALs from ovarian cancer patients. Cytokine production proﬁle of peripheral blood T cells and TALs
from patients with OC after 5h stimulation with leukocyte activation cocktail. A) Representative dot plots of IFNg and TNFa expression gated on live CD3C T cells. (B-E)
shows the respective distribution of IFNg single positive (SP), IFNg TNFa double positive (DP), TNFa SP and IFNg TNFa double negative (DN or “other”) CD3C T cells,
while (F) pie charts summarize the cytokine production proﬁle (mean) of the data represented in (B-E). OC PBMC (n D 12), ex vivo ascites (n D 12), young TAL cultures
(n D 10) and REP TAL cultures (nD 8, 4 MOCK and 4 CXCR2 transduced). Error bars designate standard deviation (SD), P <0.05, P <0.01 and P <0.001.
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Interestingly, both of the ligands for CXCR2, CXCL1 (Gro-a) and
CXCL8 (IL-8) respectively, were present at very high concentra-
tions in ascites (Fig. 2A). However, CXCR2 were not expressed
by neither T cells from ascites nor blood of patients with OC.
Maturation phenotype and cytokine proﬁle of OC T cells
and TAL cultures before and after expansion.
As CXCR2 ligands, CXCL1 (Gro-a) and CXCL8 (IL-8) were
consistently present at high concentrations in ascites from 13
individual OC patients, and CXCR2 were not expressed by T
cells, the CXCR2-ligand axis seemed a good candidate for che-
mokine receptor transduction of T cells as a means to increase
the homing of anti-tumor T cells to the tumor site.
We generated a bank of tumor ascites lymphocyte (TAL)
cultures (n D 10). As proof of principle, TALs from 4 different
patients with OC were transduced with CXCR2, using a lenti-
viral GFP-tagged construct. The distribution of na€ıve and effec-
tor T cell subsets was determined in ex vivo ascites; young
TAL; and REP TAL cultures (4 Mock and 4 CXCR2 trans-
duced), compared to that of OC PBMC (Fig. 3). CD3C cells
were divided into CD45RAC and CD45RA¡ and subgated
using CD62L and CD57. CD45RAC CD62LC na€ıve T cells
(Tna€ıve) and CD45RAC CD57C CD62L¡ T effector memory
(Temra) were most frequent in OC PBMC and decreased with
expansion of TALs (Fig. 3B-C). While Tcm decreased with
expansion of TAL, Tem frequencies signiﬁcantly increased and
made up the majority (>80%) of REP TAL cultures (Fig. 3D-F).
In addition to assessing the distribution of effector T cells, we
analyzed the effector cytokine production (IFNg and TNFa) of
OC PBMC T cells and TALs after 5h stimulation with leukocyte
activation cocktail (representative gating, Fig. 4A). While the fre-
quency of IFNg single positive (SP) “ex vivo TALs” were signiﬁ-
cantly higher than OC PBMC T cells (Fig. 4B), “ex vivo” TAL
and OC PBMC cytokine production was very similar (Fig. 4F).
The frequency of cytokine producing TALs, however, signiﬁ-
cantly decreased with in vitro culture and REP (Fig. 4B-F).
CXCR2 transduction did not alter the maturation proﬁle nor
cytokine production of REP TAL compared to their Mock trans-
duced counterparts (Fig. 3D-F and 4D-F). Furthermore, neither
genetic engineering of T cells with CXCR2 – nor IL-8 signaling
through CXCR2 – altered the tumor recognition and killing
capability by MAGE-A3 speciﬁc T cells compared to mock
transduced T cells (suppl. ﬁgure 7B-C).
CXCR2 as a potential receptor for transduction to improve
homing of T cells to tumor site
Sorted and expanded transduced cultures were phenotyped for
purity and expression of CXCR2 by ﬂow cytometry. For 3 of 4
CXCR2 transduced TAL cultures, expression of CXCR2 was
found on >80% of the TALs, compared to 0.1–0.5% of all 4
corresponding Mock transduced TAL cultures (Fig. 5, and
suppl. ﬁgure 6B).
CXCR2 transduced and corresponding Mock transduced
TAL cultures were analyzed in a 4h transwell migration assay
Figure 5. In vitro migration of CXCR2 transduced TALs. (A) Representative histogram of GFP_CXCR2 expression on CXCR2 transduced TALs, and (B) purity of sorted and
expanded TAL cultures; one Mock- and CXCR2 transduced culture from each of 4 patients with OC (Blue: RH3, Purple: RH13, Green: RH24.2 and Orange: RH35). (C) Trans-
well migration of Mock- and CXCR2 transduced TALs towards increasing concentrations of rhIL-8 (5 ng/ml, 50 ng/ml, and 100 ng/ml), or D) autologous (RH-3, RH13,
RH24.2 and RH35, respectively) or allogeneic ascites from two allo-OC patients (RH-10 and RH-22). Migration is represented as number of migrated cells / 3 £ 105 cells
(background migration subtracted)/minute. Gray squaresD CXCR2 transduced TALs, Black circles D Mock transduced TALs, Paired t-test, P < 0.05, P < 0.01.
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towards rh-IL8, autologous or allogeneic ascites. Migration was
assessed by ﬂow cytometry as the no. of migrated cells/3 £ 105
cells acquired/minute.
Transduction with CXCR2 signiﬁcantly increased the migra-
tion of TALs towards rh-IL8 (Fig. 5C). Indeed, quite low con-
centrations of rh-IL8 (5 ng/ml) induced migration of CXCR2
transduced cells. This migration was not augmented further
by increasing the concentration of rh-IL8 (50 ng/ml and
100 ng/ml respectively) underlining that IL-8 is a very efﬁcient
inducer of migration. This was supported by efﬁcient induction
of CXCR2 transduced TAL migration towards autologous asci-
tes (Range 254–467 pg/ml and 243–746 pg/ml for Gro-a and
IL-8 respectively) of the 4 patients, compared to their Mock
transduced counterparts (Fig. 5D). CXCR2 transduction was
also capable of increasing migration of 3/4 TAL cultures
towards allogeneic ascites (Fig. 5D). Migration capability
of CXCR2 and mock transduced TALs towards 5 ng/ml rh-IL8
were equal to that of engineered healthy donor T cells
(suppl. ﬁgure 7A).
Discussion
ACT has been investigated in the treatment of MM in an exten-
sive number of clinical trials, consistently showing impressive
clinical responses to treatment.7,19,20 While ACT of MM has
entered phase III clinical testing (NCT02278887), focus has
shifted to identifying other clinical malignancies that might
beneﬁt from ACT.
Early studies have investigated the potential of ACT in OC,
however, these non-randomized small studies failed to show a
measurable effect of TIL therapy,16 or were unable to show that
response rates were independent of the pre-conditioning che-
motherapy.15 In 1991, Aoki and colleagues15 already speculated
whether infrequent encounter of infused TIL with tumor was
one of several reasons for limited duration of responses
observed. Recently, several clinical phase I/II trials have been
initiated to evaluate the safety and toxicity of various forms of
ACT in patients with OC from ACT of TIL (NCT02482090) or
TIL in combination with dendritic cell re-stimulation
(NCT01883297) or checkpoint inhibition (NCT01174121).
However, these strategies will not be efﬁcient without effective
homing of TILs to the tumor site after intravenous transfer.
Tumor inﬁltration by T cells (inﬂamed tumors) identiﬁes a
group of patients with a better prognosis1,21 and response to
immunotherapy, compared to patients with non-inﬂamed
tumors.2,22 Zhang and colleagues have shown that intratumoral
T cells correlates with improved clinical outcome in advanced
ovarian cancer. This T cell inﬁltration is associated with intra-
tumoral lymphocyte-attracting chemokines, CXCL9, CCL21
and CCL22.4
In the current study, we characterized the chemokine/che-
mokine receptor proﬁle of 10 selected chemokines and their
respective receptors on T cells in ascites and blood from
patients with OC.
CCL22 has been shown to recruit highly functional immune
suppressive Tregs23-25 to the tumor and ascites of OC. We
observed higher frequencies of Tregs in PBMC and ascites
from patients with OC and a trend of Treg enrichment from
blood to ascites in a CCR4 associated manner. Adding to this,
we found consistently high levels of CCR4 ligand CCL22 in
ascites. While CCR4 ligand CCL17, was present in ascites, the
level was negligible. This corresponds well with ﬁndings by
Curiel et al.25 that CCL22 and not CCL17 is responsible for
Treg recruitment in OC. Thus, our data, in concert with
others,24,26 strongly supporting the existence of this CCL22/
CCR4 recruitment axis in OC directing Tregs from the circula-
tion into the tumor macroenvironment. As Tregs have long
been implicated in fostering suppression of anti-cancer
immune responses, it might be of interest to augment response
to immune therapy and anti-tumor immunity by abolishing
Treg recruitment. To this end, several clinical trials are cur-
rently evaluating safety, toxicity and immune regulatory prop-
erties of anti-CCR4 depletion in ovarian- (NCT01929486) and
other solid cancers (NCT02281409).
In addition to the CCR4/CCL22 axis, we studied several
other potential T cell recruitment axes in OC. Corresponding
well with data from Zhang et al.,4 we found that high concen-
trations of CXCR3 ligands, CXCL9 and CXCL10 associated
with an enrichment of CXCR3C T cells in ascites. The ﬁnding
that CXCL9 and CXCL10 concentrations were higher in ascites
compared to plasma from patients with OC, suggests a chemo-
tactic gradient for recruitment of activated T cells in OC. This
corresponds well with both ﬁndings in human ovarian cancer27
and several mouse models implicating a role for tumor
CXCL10 and CXCR3 expression on T cells, in anti-tumor
immunity.28,29
Ascites and PBMC from OC were obtained from two differ-
ent patient cohorts, which were different in terms of primary
surgery (n D 8/14) or chemotherapy (n D 2/14). This is
reﬂected in the signiﬁcantly lower serum CA125 in the PBMC
cohort compared to the ascites cohort, as treatment is expected
to kill CA125 producing malignant tissue.30,31 All other param-
eters were similar between the cohorts. Additionally, CD4/CD8
distribution was identical across the cohorts (data not shown).
Nevertheless, samples from two cohorts limits the options and
power of the statistical analyses. Despite this, we observed che-
mokine gradients between OC plasma and OC ascites in the
two cohorts (suppl. Fig. 4) matching an enrichment of CCR4C
Treg and CXCR3C and CXCR4C T cells in ascites compared to
OC PBMC.
Taken together, this suggest that a single chemokine/chemo-
kine receptor axis can signiﬁcantly improve recruitment of spe-
ciﬁc cell subsets to the tumor site. However, despite our
ﬁndings that CCR4C, CCR5C, CXCR3C and CXCR4C T cells
are enriched in OC ascites compared to OC PBMC frequencies,
all TALs cultures express CCR5 and CXCR3 after in vitro
expansion (Suppl. ﬁgure 6). In concert with extensive ex vivo
data showing that activated human T cells express CCR5 and
CXCR3,32-34 it seems futile aiming to improve homing to tumor
site by TAL engineering with either of the receptors. We did
however observe a decrease in CCR2 and CXCR4 expression
by TALs after REP (representing the infusion product) and one
might speculate whether either of these axes could be potential
candidates for future chemokine receptor engineering in OC.
While the chemokine/chemokine receptor system is quite
redundant, offering many different ligands to individual recep-
tors, we found consistently high levels of Gro-a (CXCL1) and
IL-8 (CXCL8), while the receptor CXCR2 is not expressed on T
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cells. Thus, we hypothesized that TALs could be genetically
engineered to constitutively express CXCR2, and thus improve
the homing of TALs towards ovarian cancer ascites.
As proof of concept, we generated CXCR2- and Mock trans-
duced TAL cultures from 4 individual OC patients. We are, to
our knowledge the ﬁrst to expand and chemokine receptor
transduce human ovarian cancer TALs. Ex vivo TAL were
slightly skewed towards a Tem/Tcm phenotype compared to
OC PBMC T cells containing are larger fraction of Tna€ıve cells.
This resembles a similar trend found by others.26 Quite inter-
esting, despite the frequency of Tem signiﬁcantly increasing
with expansion of TALs, mirroring the Tem dominance in TIL
products from renal cell carcinom,35 melanoma and gastroin-
testinal tumor,34 the frequency of T cells producing effector
cytokines IFNg and TNFa decrease with expansion. To this
end, it is not an uncommon observation in expanded TIL cul-
tures including melanoma36 and ovarian cancer (Westergaard
MCW et al., ESMO IO 2016, manuscript in preparation). We
unfortunately did not have access to autologous nor HLA-
matched ovarian cancer cell lines, and thus could not test the
killing capacity of in vitro cultured and expanded TALs. How-
ever, in our hands, forced expression and signaling through
CXCR2 does not affect antigen speciﬁc killing of melanoma cell
lines by T cell receptor engineered HD peripheral blood T cells
(suppl. ﬁgure 7B-C).
To this end, in vitro culturing and expansion may exhaust a
large fraction of the TALs, however, one could speculate, that
as REP TAL represents a 1000-fold expansion, the absolute
number of cytokine producing Tem increase.36
CXCR2 transduction increased the speciﬁc migration of
TALs towards rhIL-8 and autologous ascites. As little as 5ng/
ml rhIL-8 induced maximum migration of CXCR2 transduced
TALs in vitro, and increasing the concentration of rh-IL8 (50
and 100ng/ml respectively) did not increase migration, sug-
gesting that IL-8 is a potent inducer of migration, even at low
concentrations. This was conﬁrmed by induction of similar
high levels of migration of CXCR2 transduced TALs towards
autologous ascites (Gro-a and IL-8 concentration of 254–
467pg/ml and 243–746 pg/ml respectively). Additionally,
migration towards allogeneic ascites of 3 out of 4 TALs was
greater than their mock transduced counterparts. One CXCR2
transduced TAL culture (RH13) was unable to increase hom-
ing towards allogeneic ascites. Purity of CXCR2C TALs in
this culture was only around 60% and could explain these
data. However, “background” migration of these cells was
near maximal migration leaving the window for improved
migration through CXCR2 very narrow. Though the four
CXCR2- and Mock transduced TAL cultures had similar che-
mokine receptor expression patterns (Suppl. ﬁgure 6), we did
not test for all approx. 20 known chemokine receptors, nor
the ascites for all 50 known chemokine,37 thus the high back-
ground migration of the RH13 TAL culture could be
explained by donor-speciﬁc chemokines/chemokine receptor
axes not studied in the current study.
Taken together, our data suggests that the IL-8/Gro-a axis is
a universal axis in OC, which can be exploited to improve hom-
ing of T cells after genetic engineering with CXCR2. Given the
fact that IL-8 is expressed in other tissues under certain condi-
tions, e.g., inﬂammation, patients suffering from chronic
inﬂammatory- or auto-immune diseases should be excluded
from clinical trial testings based on this approach.
Transduced TALs are of a Tem phenotype capable of pro-
ducing pro-inﬂammatory cytokines IFNg and TNFa upon
stimulation. Despite being solely in vitro generated, our data is
supported by similar in vivo studies successfully redirecting T
cells towards melanomas with CXCR238 in syngeneic mouse
models, as well as ACT of xenograft human mesothelioma
and neuroblastoma using CCR2b transduced human T cells,
respectively.39,40 Additionally, CXCR2 redirected TILs are
currently under investigation in a Phase I/II clinical trial of
ACT in melanoma (NCT01740557).
Conclusion
We hypothesized that ascites chemokines could be exploited for
optimizing tumor homing of T cells, and we identiﬁed several
chemokine-chemokine receptor axes, most prominently the
CXCR2/IL8 axis due to absence of IL-8 receptors on T cells
prior to genetic engineering.
CXCR2 redirected TILs are currently under investigation in
a Phase I/II clinical trial of ACT in melanoma (NCT01740557).
Our data show that IL8 is uniformly present in OC ascites and
the introduction of CXCR2 in TALs lead to improved migra-
tion towards ascites. Thus, redirection of TALs is feasible, and
pose as suited candidate for clinical translation in ACT in OC.
ACT of CXCR2 redirected TALs (or TILs, or CART cells) could
be combined with CCR4 antibody depletion (e.g. Mogamulizu-
mab) of immune suppressive Treg, thus concurrently improve
homing of T cells for ACT and inhibit tumor homing of Treg.
Materials and methods
Patient material/Samples
This project includes samples from patients with serous adeno-
carcinoma of the ovaries from two parallel studies. Ascites was
obtained during primary open surgery from 13 treatment na€ıve
OC patients of serous histology included in the Pelvic Mass
study, while blood samples for isolation of peripheral blood
mononuclear cells (PBMCs) were obtained from 14 OC
patients of serous histology included the STAT0206 study,
most with prior treatment – a majority having undergone
primary surgery, and 2 having received prior chemotherapy.
The majority of patients included in this project had stage III-
IV disease (n D 22 of 27 patients included), and were treated at
Department of Oncology at Herlev University Hospital, or Rig-
shospitalet, Copenhagen University Hospital, Denmark. Patient
characteristics are presented in suppl. table 1. Median age was
65 years (range 45–81). Buffycoats from 13 healthy donors
from the blood bank at Rigshospitalet, Copenhagen, Denmark
were used as healthy PBMC controls (mean age 38.5 years, esti-
mated range 17–67, median unknown). The studies (Ascites
and PBMC) were all approved by the Danish Ethics Committee
of Human Experimentation, approval no. H-3–2010-022 and
H-2–2010-054, respectively. Informed written consent was
obtained from all patients and healthy donors before inclusion.
Blood samples of 60ml obtained by venipuncture were collected
in Li-heparin tubes from each patient, and transported at room
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temperature. Processing was completed within< 6h for all sample
specimens. PBMC were isolated by density gradient centrifugation
with LymphoprepTM (Axis-Shield PoC, #1114547), (30 minutes at
1200 RPM, without break) and cryopreserved at -150C in fetal
bovine serum (FBS) (GibcoBRL, #10270106)C 10% dimethylsulf-
oxide (DMSO) (Sigma-Aldrich, #D5879).
Ascites was obtained in large containers during open surgery
at the surgery room at Rigshospitalet. Upon arrival at the lab,
ascites samples were added 1ml penicillin/streptomycin
(Gibco, #15140–122) pr 100ml ascites and placed in the incuba-
tor for overnight incubation at 37C. Overnight incubation
should see tumor and myeloid cells adhere to the plastic, allow-
ing harvest of cell free ascites and non-adherent lymphocytes.
Cell free ascites were centrifuged for 5 minutes at 1500 rpm to
remove any cells and debris (clariﬁed ascites), and stored at
-20C until use. Non-adherent cells were washed twice in
RPMI 1640 (Life Technologies, #72400054) centrifugation for
5 min at 1500rpm, and cryopreserved at -150C in FBS C 10%
DMSO C 10%.
Flow cytometry and cell sorting
Multicolor ﬂow cytometry was performed on PMBC from
healthy donors and OC patients as well as cells from OC ascites
and TAL cultures.
All ex vivo analyses was performed on freshly thawed cells.
2–5 £ 105 cells were stained in 5 ml Falcon tubes (BD) with a
mix of ﬂuorochrome conjugated monoclonal antibodies (mAb).
For characterization of chemokine receptor expression, all
samples were stained with mAbs to CD3-BV421 (Biolegend,
clone: UCHT1, cat #300434), CD8-FITC (BD Biosciences, clone:
RPA-T8, cat #561948), CD4-PE-Cy7 (BD Biosciences, clone: SK3,
cat #557852). Chemokine receptor expression was assessed by
labeling cells with a cocktail of either CXCR2-APC (Biolegend,
clone: 5E8/CXCR2, cat #320710), CXCR3-BV510 (Biolegend,
clone: G025H7, cat #353726), CXCR4-PE (Biolegend, clone:
12G5, cat #306506), or CCR2-APC (Biolegend, clone: K036C2,
cat #357208), CCR4-BV510 (Biolegend, clone: L291H4, cat
#359416) and CCR5-PE (Biolegend, clone: J418F1, cat# 359106).
Maturation proﬁle was assessed using a cocktail of mAbs to
CD3-BV421 (Biolegend, clone: UCHT1, cat #300434), CD8-
FITC (BD Biosciences, clone: RPA-T8, cat #561948), CD4-
BV510 (Biolegend, clone: OKT4 cat # 317444), and maturation
markers CD57-PE (Biolegend, clone: HCD57, cat # 322312),
CD45RA-PerCP-Cy5.5 (Biolegend, clone: HI100, cat # 304122)
and CD62L-APC (Biolegend, clone: DREG-56, cat #304810).
Appropriate ﬂuorochrome conjugated isotype controls were
included for all chemokine receptors and maturation markers.
A near-infrared ﬁxable dead cell stain (Life technologies,
#L10119) was included for dead cell exclusion. Staining was
performed for 20–30 minutes protected from light and on ice.
Cells were washed twice prior to and twice post mAb staining
with 1x PBS C 2% FBS (FACS buffer).
For analysis of Treg frequencies, all samples were stained with
mAbs to CD3-FITC (Biolegend, clone: HIT3a, cat #300306), CD8-
PerCP (Biolegend, clone: RPA-T8, cat #301029), CD4-APC (Biole-
gend, clone: RPA-T4, cat #300514), CD127 PE-Cy7 (Biolegend,
clone: A019D5, cat #351319), CD25-BV421 (Biolegend, clone:
B96, cat #302630) and CCR4-BV510 (Biolegend, clone: L291H4,
cat #359416), as well as near-infrared ﬁxable dead cell stain (Life
technologies) for dead cell exclusion according to the above extra-
cellular staining (ECS) procedure. After the second wash post ECS
mAb staining, the cells were ﬁxed and permeabilized using the
FoxP3/Transcription factor staining buffer set from Affymetrix
eBiosciences (#00-5523-00), according to manufacturer’s recom-
mendations. In short, cells were ﬁxed in ﬁxation/permeabilization
buffer for at least 1h, alternatively overnight. After appropriate ﬁxa-
tion, the cells were washed twice using Permeabilization wash
buffer and stained with mAb to FoxP3-PE (eBioscience, clone:
FJK-16s, cat #12–5773-82) or appropriate isotype control, for
20–30minutes protected from light on ice. After intracellular stain-
ing for FoxP3, the cells were washed twice with Permeabilization
wash buffer.
For assessment of cytokine proﬁle, OC TALs and PBMC
were thawed and rested overnight prior to 5h stimulation with
leukocyte activation cocktail (BD Biosciences, cat # 550583) or
BD GolgiPlugTM (negative control, BD Biosciences, cat #
555029). After stimulation, cells were stained with mAbs to
CD3-BV421 (Biolegend, clone: UCHT1, cat #300434), CD8-
FITC (BD Biosciences, clone: RPA-T8, cat #561948), CD4-
BV510 (Biolegend, clone: OKT4 cat # 317444), and intracellular
cytokines; IFNg-PE (eBioscience, 4S.B3, cat #12–7319-42),
TNFa-APC (BD Biosciences, clone: Mab11, cat #554514) and
IL-17A-PerCP-Cy5.5 (eBioscience, clone: eBio64DEC17, cat
#45–7179-4), according to the procedure described above.
Samples for chemokine receptor characterization, Treg fre-
quencies, maturation and cytokine proﬁle were acquired on a
BD FACS Canto II (BD Biosciences, New Jersey, USA) within
1h of ﬁnishing staining procedure and all data was analysed
with BD FACSdiva software version 8.0.1.
Due to insufﬁcient sample material, maturation and cyto-
kine proﬁling was only performed on 12 of the 14 OC PBMC
and 12 of the 13 OC ascites samples.
For sorting, transduced TAL cultures were labelled accord-
ing to above described ECS staining protocol with mAbs to
CXCR2-APC (Biolegend) and CD3-BV421 (Biolegend). A
near-infrared ﬁxable dead cell stain (Life technologies) was
included for dead cell exclusion. Lentivirally transduced TALs
co-expressing GFP and CXCR2 were sorted (designated
“CXCR2”). GFP¡ CXCR2¡ double negative T cells were sorted
as the “non-transduced” control TALs (Designated “Mock”).
MAGE-A3 TCR transduced healthy donor T cells were sorted
using anti-Vb5.1 TCR-APC (eBioscience, clone: LC4, cat # 17–
5832-42) and CD3-BV421 (Biolegend). All antibodies, buffers
and procedures were kept under sterile conditions to ensure
aseptic sorting of cells for further culturing. Cell sorting
was performed on a BD FACS aria (BD Biosciences,
New Jersey, USA).
Setup of the instruments, quality control and compensation
settings were done according to instrument requirements.
Luminex
Cell free ascites samples were analyzed for CCL2/MCP-1, CCL17,
CCL22, CXCL1/Gro-a, CXCL8/IL-8, CXCL9, CXCL10, CXCL11
and CXCL12/SDF-1 using a multiplex Bio-Plex ProTM Human
Chemokine assay (BioRad, #171AK99MR2), and CCL5/RANTES
Bio-Plex Pro Human Cytokine Assay (BioRad #171B5025M).
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Samples were prepared according to manufacturer’s recommenda-
tions. In short, 50ml of freshly thawed samples and prepared stand-
ards were transferred to designated wells in the 96-well plate, with
each well containing 50 ml magnetic bead solution. The plate was
incubated on a shaker for 1hr (850 rpm, the setting for all following
incubation). Next, 25ml detection antibody was added to each well
and the plate was incubated on shaker for 30 min. in dark. Last,
50 ml streptavidin was added and the plate incubated for 10 min.
on shaker in dark. The plate was washed 3 times between all incu-
bation steps.
The samples were acquired on a Bio-Plex 200 system (Bio-
Rad, CA, USA) and analyzed with Bio-Plex ManagerTM v.6
software.
TAL isolation protocol, transduction and rapid expansion
Tumor ascites T lymphocyte (TAL) cultures were established
by expansion of ascites T cells using high dose rhIL-2 (Proleu-
kine, Novartis, order by prescription) of 6000U/ml. In short,
ascites cells were plated 1 £ 106 cells pr well in a 24-well plate
containing X-vivo (Lonza, #LZ-BE-04-418Q) C 5% human AB
serum (HS, Sigma Aldrich, #H4522) C 6000U/ml rhIL-2. The
cells were left for the initial 5 days in a 37C humidiﬁed CO2
incubator, after which, the medium was changed every
2–3 days by removal of 1ml medium and addition of 1ml fresh
medium, without resuspending the cells. Within 7–10 days,
T cells started to grow out, ﬁrst in clusters, before becoming
conﬂuent (covering >90% of the well bottom). When T cells
reached conﬂuence, the cells were resuspended and split
1:2 into adjacent wells. “Young” TAL cultures were cryopre-
served according to protocol described above when cell counts
of > 50 £ 106 T cells were reached (13 cultures, range; 14–28
days) in culture.
Lentiviral transduction of TALs and healthy donor T cells
The cDNA encoding CXCR2 (accession nr. NM_001557) was
synthesized and cloned into the lentiviral vector pTRP-EGFP
(generously provided by Dr. James L. Riley, University of Penn-
sylvania, Philadelphia, PA) using 5`AvrII/30SalI restriction sites
(GeneArt/ Thermo Fisher Scientiﬁc, Regensburg, Germany)
generating pTRP-EGFP_CXCR2. This vector permits dual
expression of EGFP and CXCR2 from a single RNA transcript.
Lentiviral vector containing high afﬁnity MAGE-A3a3a
TCR24 and corresponding packaging and envelope plasmids
(VSVG, REV and gag/pol) was generously provided under
MTA.
Lentivirus was produced after transfection of 293T human
embryonic kidney cells cultured in DMEM (BioWhittaker,
Rockville MD, USA), 10% FBS. 293T cells were seeded at 5 £
105 per well in a 6-well plate 24h before transfection. Lentivirus
was produced after transfection of 293T human embryonic kid-
ney cells (HEK293 T/17 ATCC, #ACS-4500) cultured in
DMEM (BioWhittaker, #31966-047), 10% FBS, Cells were
seeded at 5 £ 105 per well in a 6-well plate 24 h before transfec-
tion. For transfection, 1 mg of pMAGE-A3a3a or pTRP-
EGFP_CXCR2 and 0.5 mg of corresponding packaging and
envelope plasmids were used together with TurboFect Trans-
fection Reagent (Thermo Fisher Scientiﬁc). Cells were cultured
at humidiﬁed atmosphere with 5% CO2 for 48 hours before
harvesting the viral supernatant. For transduction of TALs and
healthy donor T cells, T cells were incubated with lentivirus ﬁl-
tered supernatant C 6000 U/ml rhIL-2 for 72 hours before
being sorted using a FACSAria cell sorter (BD Biosciences, San
Jose CA, USA). Routine assays for gene expression via ﬂow
cytometry and for mycoplasma were conducted and CXCR2-
transduced TALs and healthy donor T cells were used for
experimental analysis as indicated.
1–2 £ 105 transduced and sorted TALs and healthy donor T
cells were put into a rapid expansion protocol (REP) along with
20 £ 106 feeder cells (PBMC from 4 donors, gamma irradiated
with 40 Gy) in a T25 tissue culture ﬂask (Corning, #430168) in
20 ml x-vivo medium C 5% HS, 30 ng/ml anti-CD3 (OKT-3,
eBioscience, #14-0037-82) and 6000 U/ml rhIL-2. REPs were
incubated undisturbed for the initial 5 days after which, half of
the cell culture medium was changed every 2–3 days. When
expanding cells covered the bottom of the ﬂasks, all content
was transferred to T75 ﬂasks and kept in 40ml culture medium.
Anti-CD3 was only added at the setup of REP, 6000 U/ml
rhIL-2 was continued throughout the REP. On day 14 of REP,
the cells were harvested and 2 £ 105 cells of each culture were
analyzed for GFP-CXCR2 and TCR purity. Remaining cells
were cryopreserved according to the PBMC protocol described
above and kept at -150C until use.
Transwell migration assay
Chemokine mediated migration was assessed using a
Transwell system. 3 £ 105 TALs in a volume of 200 ml serum
free medium (x-vivo) was added to the upper chamber
containing a 3 mm polycarbonate membrane (Corning,
#CLS3415-48A), and chemotaxis towards the lower chamber
containing either 500 ml x-vivo C 5–100 ng/ml rhIL-8 (R&D
systems, #208-IL-010) or 500 ml (autologous or allogeneic)
malignant ascites. 1 well pr. TAL culture was used as a control
for background migration (minimum migration) with serum
and chemokine free medium in the lower chamber, while
another well was added cells directly into the lower chamber
without a transwell membrane to represent the maximum
migration. The assay was incubated for 4 h at 37C, before
counting the number of migrated cells in the bottom well by
ﬂow cytometry. In short, transwell inserts were discarded and
the cells in the bottom well were resuspended and transferred
to 5 ml Falcon tubes (VWR, #60819-138). The wells were
washed by 1 ml FACS buffer to ensure recovery of all migrated
cells. Cells were spun once and all of the supernatant was
removed, before resuspending the cells in exactly 100ml per
tube. Immediately prior to acquisition on a BD FACS canto II
ﬂowcytometer, all samples were added 2 ml 7-AAD (BD bio-
sciences, #51-68981E) for dead cell exclusion. The samples
were acquired using an automated carousel, at high ﬂow rate,
for precisely 60 seconds each, generating a value of number (#)
of migrated cells / 3 £ 105 cells/ minute.
51Crrelease cytotoxicity assay
MAGE-A3 TCR speciﬁc healthy donor T cells were put into
51Cr release cytotoxicity assay to evaluate the killing capacity of
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CXCR2 or Mock transduced against IL-8 secreting melanoma
cell line FM82 alone or in combination with either 50 ng/mL
IL-8, or 2 ug/mL neutralizing mAb to IL-8. In short, 5 £ 105
target cells (FM82) were labeled with 100 mCi 51Cr (Perkin
Elmer) in 100 mL RPMI C 10% FBS for 60 min. Washed 51Cr
labelled target cells were subsequently plated 5 £ 103 cells/well
in round bottomed 96-well plates with T cells at decrescendo
effector:target ratios, and incubated 4 h at 37C. 100 mL super-
natant was aspirated and 51Cr-release was measured using a
gamma counter (Perkin Elmer Wallac Wizard 1470 Automatic
gamma counter) for quantiﬁcation of T cell-mediated killing of
target cells. Additional wells were used to determine maximum
and spontaneous 51Cr release. Maximum 51Cr release were
assessed by lysing target cells with 100 mL 10% TritonX-100
(Sigma-Aldrich) while spontaneous 51Cr release was measured
on target cells added 100 mL RPMI 1640 C 10% FBS only. Spe-
ciﬁc lysis was calculated using the following equation; ((sample
release – spontaneous release)/(maximum release – spontane-
ous release))100%.
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